Genotype Guided Antiplatelet Therapy In Ischemic Stroke
Ischemic Stroke, Transient Ischemic Attack
About this trial
This is an interventional treatment trial for Ischemic Stroke focused on measuring Genotype Guided Antiplatelet Therapy
Eligibility Criteria
Inclusion Criteria: Patients diagnosed with acute ischemic stroke or transient ischemic attack. Age 21 years to 100 years. Can be randomised within 7 days of onset of index event [Refer to footnote 1]. Clopidogrel naive immediately prior to index event [Refer to footnote 2]. Footnote 1: Date of index event to be taken as Day 1. This means that randomisation must be done by Day 7. For unknown onset or wake-up stroke where the last seen well and symptoms discovery are on different days, Day 1 is taken to be the date of symptoms discovery. Footnote 2: Patients who were on short-term antiplatelets which included clopidogrel but are no longer on clopidogrel prior to stroke would fulfil for this inclusion criteria. In this context, short-term antiplatelets are defined as 21 days for minor stroke TIA and 3 months for large vessel disease. Exclusion Criteria: Known diagnosis of dementia [Refer to footnote 3]. Known diagnosis of a life limiting illness with life expectancy of less than 1 year. Known cardioembolism or prothrombotic state necessitating the use of anticoagulation, or having a contraindication to clopidogrel. Footnote 3: "Known diagnosis of dementia" will be defined as clinical diagnosis of dementia prior to the index stroke event as indicated in the patient's medical records.
Sites / Locations
- Singapore General HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Genetic testing
Standard medical therapy
Patients randomised to testing will have blood drawn for testing of CYP2C19 LOF mutations. Physicians of patients who test positive for an LOF mutation (intermediate and poor metabolizers) will be notified of the mutation with recommendations of possible alternative antiplatelet regimens suggested. Aspirin will be the recommended monotherapy, and aspirin in combination with ticagrelor or dipyridamole will be the recommended dual antiplatelet regimen. Decision of alternative medications used in patients with LOF mutations will be left to the discretion of the primary physician. Patients in the genotype guided antiplatelet therapy group who do not have LOF mutations will be left to continue the original intended antiplatelet regimen (this may be clopidogrel monotherapy, or in combination with aspirin). No randomisation for patients with known CYP2C19 status prior to recruitment as these patients will be recruited as a comparison arm for outcomes measurements.
Patients on this arm will be placed on clopidogrel monotherapy, or in combination with aspirin, which is the original intended antiplatelet regimen.